logowsbdaily | Tue, 25 Jan 2022 08:54:43 EST Where you find Tomorrow’s Hot Stocks Yesterday! 

NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.

Arbutus Biopharma Corporation
(ABUS)

Arbutus Biopharma Corporation
701 Veterans Circle
Warminster, PA 18974
United States
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalentl... Read More

Summary & Charts

Price$ 4.14-0.22 (-5.05%)
Day's Range$ 4.02 - 4.58 
Previous Close$ 4.36
Market Cap$ 425.1M USD
Short Interest %N/A
FloatN/A
OutstandingN/A
ExchangeNasdaqGS
IndustryBiotechnology
SectorHealthcare
Volume8.29M
Avg. Volume (20 day)24.89M
Rel. Volume (20 day)0.33
Rel. Volume (3 month)0.89
RatingBNeutral
DCFN/AStrong Buy
Debt/Equity27.24 %Neutral
ROE-64.39 %Sell
ROA-43.46 %Sell
P/E-5.83 %Strong Sell
P/B3.22 %Strong Buy
DateOpenHighLowCloseChangeVolumeR. Vol. (20d)R. Vol. (3m)Mentions
Dec 14, 2021$ 4.25$ 4.58$ 4.02$ 4.14-0.228,288,1850.330.89
Dec 13, 2021$ 4.38$ 4.50$ 4.14$ 4.36+0.227,725,4500.310.84
Dec 10, 2021$ 4.50$ 4.67$ 4.11$ 4.14-0.177,098,0810.290.75
Dec 09, 2021$ 4.11$ 4.59$ 4.08$ 4.31+0.1712,376,6290.521.35
Dec 08, 2021$ 3.90$ 4.26$ 3.83$ 4.14+0.187,968,6530.340.903
Dec 07, 2021$ 3.98$ 4.10$ 3.79$ 3.96+0.2519,802,6600.862.28
Dec 06, 2021$ 3.99$ 4.01$ 3.54$ 3.71-0.4410,061,8970.451.21
Dec 03, 2021$ 4.05$ 4.45$ 3.92$ 4.15-0.1618,237,4780.842.22
Dec 02, 2021$ 4.97$ 5.23$ 4.11$ 4.31-0.3072,310,9953.449.201
Dec 01, 2021$ 5.15$ 6.50$ 4.13$ 4.61+1.41322,153,88918.4447.5012
Nov 30, 2021$ 3.10$ 3.23$ 3.01$ 3.20+0.061,476,3811.030.63
Nov 29, 2021$ 3.20$ 3.20$ 3.08$ 3.14+0.011,245,2560.860.53
Nov 26, 2021$ 3.18$ 3.21$ 3.08$ 3.13-0.06651,8620.450.28
Nov 24, 2021$ 3.10$ 3.21$ 3.05$ 3.19+0.07720,6790.490.30
Nov 23, 2021$ 3.10$ 3.13$ 3.02$ 3.12+0.011,286,1520.860.53
Nov 22, 2021$ 3.27$ 3.31$ 3.09$ 3.11-0.191,543,2411.040.64
Nov 19, 2021$ 3.28$ 3.37$ 3.27$ 3.30924,8270.620.38
Nov 18, 2021$ 3.40$ 3.51$ 3.27$ 3.30+0.011,657,8701.070.68
Nov 17, 2021$ 3.30$ 3.37$ 3.24$ 3.29-0.051,096,9320.710.44
Nov 16, 2021$ 3.32$ 3.40$ 3.25$ 3.34-0.021,231,1940.790.49

News

The latest news about Arbutus Biopharma Corporation (ABUS).

Benzinga | 2021-12-13 10:19:35
Arbutus Biopharma Corp (NASDAQ: ABUS) shares are trading higher after the company announced it received a $40M upfront payment from Qilu to commercialize AB-729 in Asia. William Collier, President and Chief Executive Officer of Arbutus Biopharma, commented, "Qilu is an ideal partner for our AB-729 RNAi therapeutic given their extensive development, regulatory and commercialization capabilities in China.
PennyStocks | 2021-12-10 16:08:33
Got $5 to spend on penny stocks? Take a look at these four for your watchlist The post Got $5 to Spend on Penny Stocks?
PennyStocks | 2021-12-09 13:42:51
Are these Reddit penny stocks on your watchlist right now? The post 4 Penny Stocks That Are Trending on Reddit Right Now and Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks | 2021-12-08 14:26:06
Analysts are bullish on these penny stocks in 2021. Should you be?
Pulse2 | 2021-12-07 13:38:02
The stock price of Arbutus Biopharma Corp (NASDAQ: ABUS) increased by over 10% during intraday trading today. This is why it happened.
Benzinga | 2021-12-07 09:24:13
Arbutus Biopharma Corporation (NASDAQ: ABUS) has identified several molecules that inhibit the SARS-CoV-2 nsp5 main protease (Mpro), a validated target for treating COVID-19 and potential future coronavirus outbreaks.  In April 2021, Arbutus, X-Chem Inc, and Proteros biostructures GmbH entered a discovery research and license agreement of novel inhibitors targeting the SARS-CoV-2 nsp5 main protease.
Business Insider | 2021-12-01 14:43:38
The patents subject to the court's ruling cover a lipid formulation for nucleic acid delivery, which is essential for Moderna's COVID-19 vaccines.

Earnings

DateTimeEPS ExpectedEPS Reported%Revenue ExpectedRevenue Reported%
2021-11-04BMO-0.24-0.24--2.4M3.3M40.33%
2021-08-05BMO-0.21-0.239.52%2.1M2.3M9.85%
2021-05-05BMO-0.23-0.218.7%3.3M2.1M-35.97%
2021-03-04BMO-0.22-0.234.54%2M2.4M17.53%
2020-11-05BMO-0.22-0.2722.72%1.2M1.5M22.72%
2020-08-07BMO-0.24-0.254.16%1.5M1.5M4.16%
2020-05-11BMO-0.31-0.2519.36%1.8M1.5M-19.36%
2020-03-05BMO-0.36-0.4627.77%1.3M1.6M27.77%

Top Discussions

These are the top discussions over the last 24-hours that mention the ABUS stock ticker symbol.


Failures to Deliver

Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.

Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.

Last Updated: Tue, 14 Dec 2021 12:00 EST


Support & Feedback

Got feedback or suggestions for more awesomeness? Or wanna keep up to date with changes?

@wsbdaily@wsbdailywsbdaily subredditwsbdaily

No obligation, if you'd like to support us with development and hosting costs then

Buy Me A Coffee

Disclaimer

WE ARE NOT AFFILIATED WITH REDDIT, THE LEADERSHIP OR MODERATOR TEAMS OF ANY OF THE SUBREDDITS WE CRAWL NOR WITH ANY OTHER WEBSITE, COMPANY OR DATA PROVIDER FROM WHICH WE PULL AND/OR AGGREGATE DATA FROM.

ALL CONTENT ON THIS SITE IS SOLEY FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY. THE SITE AND CONTENT, ARE PROVIDED “AS IS” AND WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. ANY CONTENT OR STATEMENT HEREIN SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, OR AS AN OFFER TO BUY, SELL, OR SOLICIT THE PURCHASE OR SALE OF ANY SECURITY OR FINANCIAL INSTRUMENT. DO YOUR OWN DUE DILIGENCE.

THE INFORMATION ON THIS SITE IS NOT UPDATED IN REAL-TIME, EACH DATASET SPECIFIES WHEN IT WAS “LAST UPDATED”. MOST INFORMATION IS CURRENTLY INDEPENDENTLY PERIODICALLY UPDATED EVERY 30 TO 150 MINUTES AND ONLY WHEN THE MARKETS ARE CLOSED. YOU BEAR ALL RISKS ASSOCIATED WITH THE USE OF THE SITE AND CONTENT, INCLUDING WITHOUT LIMITATION, ANY RELIANCE ON THE ACCURACY, COMPLETENESS OR USEFULNESS OF ANY CONTENT AVAILABLE ON THE SITE. YOUR USE OF THE INFORMATION CONTAINED HEREIN IS SOLELY AT YOUR OWN RISK. DO YOUR OWN DUE DILIGENCE.

There are high risks associated with investing in securities. Investing in stocks, options, bonds, ETFs, mutual funds, and money market funds involve risk of substantial loss. Loss of principal is possible. Some high risk investments may use leverage, which will greatly accentuate any losses. Foreign investing involves special risks, including a greater volatility and political, economic and currency risks and differences in accounting methods. Any past investment performance is not a guarantee or predictor of future investment performance. DO YOUR OWN DUE DILIGENCE.

The software providing the content on this site is currently in an alpha state. Although care is taken to publish accurate data inaccurate information is very, very possible. Use at your own risk. DO YOUR OWN DUE DILIGENCE.